We suggest that these activities may reflect, in part, daratumumab mediated “trogocytosis” of CD38 (i.e., the transfer of the target molecule, CD38, together with bound antibody from the tumor cell to phagocytes mediated by FcγRs on the acceptor cells), and so the issue may be more complex [132,134]. This evidence concerns the gene CD38 and neoplasm.